Purdue University
Purdue University, established in 1869, is a public research university located in West Lafayette, Indiana. It is renowned for its programs in science, technology, engineering, and agriculture, offering a wide range of undergraduate and graduate degrees. The university's operations are funded through a combination of public and private sources, with a significant portion coming from its endowment. This endowment, managed by the board of trustees, is built from gifts by alumni and friends, with the investment income supporting scholarships, professorships, research, and other educational initiatives. Purdue's mission is to provide a high-quality education, conduct groundbreaking research, and engage in outreach activities that serve the state, nation, and world.
Top Regions
Top Stages
3 past transactions
Kaplan University
Acquisition in 2017
Kaplan University is an educational institution located in Davenport, Iowa, and is part of the larger Kaplan organization based in Fort Lauderdale, Florida. The university focuses on serving adult learners by offering practical, student-centered education designed to prepare them for successful careers. Kaplan University provides a range of online degree programs that cater to the needs of working professionals, allowing flexibility in education while maintaining a commitment to academic excellence and career readiness.
Davista Technologies
Seed Round in 2016
Developer of a visual analytics software designed to enable companies to make better decisions. The company's visual analytics software offers interactive business intelligence and reporting, advanced multivariate visual analytics suing enhanced correlative and prediction techniques as well as social media analytics, enabling first responders to gain situational awareness and facilitate risk-based and real-time decision making.
Kylin Therapeutics
Venture Round in 2009
Kylin Therapeutics, a biotechnology company, employs an RNA nanoparticle technology platform called “pRNA†to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. The platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome many challenges in the development of RNA-based therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.